DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial OfficerGlobeNewsWire • 10/16/23
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial ResultsGlobeNewsWire • 07/31/23
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate UpdateGlobeNewsWire • 07/25/23
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in ToddlersGlobeNewsWire • 05/10/23
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDAGlobeNewsWire • 04/19/23
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General MeetingGlobeNewsWire • 04/12/23
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years OldGlobeNewsWire • 03/07/23
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration DocumentGlobeNewsWire • 03/02/23
DBV Technologies Reports Full Year 2022 Financial Results and Business UpdateGlobeNewsWire • 03/02/23
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023GlobeNewsWire • 02/27/23
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal TrialGlobeNewsWire • 12/23/22